PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Inclisiran - Lipid modification

PAD Profile : Inclisiran - Lipid modification

Keywords :
primary hypercholesterolaemia, mixed dyslipidaemia, lipid-lowering, lipid lowering
Brand Names Include :
Leqvio

Traffic Light Status

Status 1 of 1.

Status :
Green
Important
Formulations :
  • Subcutaneous injection (sc)
Important Information :
Prescribing in secondary care is commissioned by NHSE - Blueteq forms are required.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 October 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Decision reviewed March 2022
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agree inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia in line with NICE TA733

A GREEN traffic light status will be applied to inclisiran. 

Key points:

  • It should be a shared decision making process between the patient and the prescribing clinician in line with NICE.
  • Patient should be on maximum tolerated lipid-lowering therapy prior to initiation with inclisiran.
  • Can be used in combination with statins or other lipid lowering treatments OR
  • As monotherapy only if a person was unable to take any other type of lipid-lowering therapy  

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More